Hält derzeit Positionen bei BridgeBio Pharma Inc, Genentech Inc and Alector Inc
Position | Company | Period |
---|---|---|
Chairman of Research and Development, Director | BridgeBio Pharma Inc | 1. Januar 2019 - |
Executive Vice President - Research, Chief Scientific Officer | Genentech Inc | 1. Januar 2008 - |
Independent Director | Alector Inc | 1. Oktober 2018 - |
Independent Director | Xenon Pharmaceuticals Inc | 16. März 2015 - 14. Januar 2020 |
Director | BridgeBio Pharma Inc | 1. Januar 2018 - 1. Januar 2019 |
Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | Roche Holding AG | 1. Januar 2009 - 31. Dezember 2014 |
Suchen
Datum der Benachrichtigung | Datum der Transaktion | K/V Art der Transaktion |
Anz. der Aktien Kurs Wert |
Anzahl der Aktien | Kurs | Gesamtwert | Details | |
---|---|---|---|---|---|---|---|---|
2022-11-14 | 2022-11-11 |
VG Acquisition Corp
(VGAC)
|
V Verkauf |
18.421
-20.3%
3,2459.684 USD |
18.421 -20.3% | 3,24 | 59.684 USD | |
2021-05-24 | 2021-05-24 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
100
-0.3%
25,002.500 USD |
100 -0.3% | 25,00 | 2.500 USD | |
2021-05-24 | 2021-05-21 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
1.231
-3.0%
25,1931.008 USD |
1.231 -3.0% | 25,19 | 31.008 USD | |
2021-05-24 | 2021-05-20 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
659
-1.6%
25,0816.528 USD |
659 -1.6% | 25,08 | 16.528 USD | |
2021-05-18 | 2021-05-18 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
2.800
-6.4%
25,3470.958 USD |
2.800 -6.4% | 25,34 | 70.958 USD | |
2021-05-18 | 2021-05-17 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
500
-1.1%
25,0612.530 USD |
500 -1.1% | 25,06 | 12.530 USD | |
2021-05-18 | 2021-05-14 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
4.615
-9.4%
25,38117.117 USD |
4.615 -9.4% | 25,38 | 117.117 USD | |
2021-04-05 | 2021-04-01 |
Oric Pharmaceuticals Inc
(ORIC)
|
GV Geplanter Verkauf |
200
-0.4%
25,005.000 USD |
200 -0.4% | 25,00 | 5.000 USD | |
2020-12-23 | 2020-12-21 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
45.473
-49.8%
65,482.977.699 USD |
45.473 -49.8% | 65,48 | 2.977.699 USD | |
2020-12-23 | 2020-12-21 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
14.928
-14.0%
64,81967.437 USD |
14.928 -14.0% | 64,81 | 967.437 USD | |
2020-12-21 | 2020-12-18 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
2.895
-2.7%
65,78190.432 USD |
2.895 -2.7% | 65,78 | 190.432 USD | |
2020-12-21 | 2020-12-18 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
27.105
-19.9%
64,991.761.589 USD |
27.105 -19.9% | 64,99 | 1.761.589 USD | |
2020-12-17 | 2020-12-15 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
19.352
-12.4%
60,731.175.303 USD |
19.352 -12.4% | 60,73 | 1.175.303 USD | |
2020-12-17 | 2020-12-15 |
BridgeBio Pharma Inc
(BBIO)
|
V Verkauf |
12.091
-7.2%
59,81723.114 USD |
12.091 -7.2% | 59,81 | 723.114 USD | |
2020-09-18 | 2020-09-16 |
BridgeBio Pharma Inc
(BBIO)
|
GV Geplanter Verkauf |
25.000
-15.3%
37,50937.500 USD |
25.000 -15.3% | 37,50 | 937.500 USD | |
2020-02-06 | 2020-02-04 |
Alector Inc
(ALEC)
|
GV Geplanter Verkauf |
10.000
-50.0%
29,67296.700 USD |
10.000 -50.0% | 29,67 | 296.700 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
V Verkauf |
100
-100.0%
61,616.161 USD |
100 -100.0% | 61,61 | 6.161 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
V Verkauf |
500
-100.0%
61,6030.800 USD |
500 -100.0% | 61,60 | 30.800 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
V Verkauf |
800
-100.0%
61,5949.272 USD |
800 -100.0% | 61,59 | 49.272 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
V Verkauf |
5.893
-100.0%
61,58362.891 USD |
5.893 -100.0% | 61,58 | 362.891 USD | |
2004-05-07 | 2004-05-06 |
Genentech Inc
(DNA)
|
V Verkauf |
1.354
-100.0%
124,00167.896 USD |
1.354 -100.0% | 124,00 | 167.896 USD | |
2004-05-07 | 2004-05-06 |
Genentech Inc
(DNA)
|
V Verkauf |
2.604
-100.0%
124,00322.896 USD |
2.604 -100.0% | 124,00 | 322.896 USD |